BR112021024151A2 - Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho - Google Patents

Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho

Info

Publication number
BR112021024151A2
BR112021024151A2 BR112021024151A BR112021024151A BR112021024151A2 BR 112021024151 A2 BR112021024151 A2 BR 112021024151A2 BR 112021024151 A BR112021024151 A BR 112021024151A BR 112021024151 A BR112021024151 A BR 112021024151A BR 112021024151 A2 BR112021024151 A2 BR 112021024151A2
Authority
BR
Brazil
Prior art keywords
eye
protein aggregation
pharmacological agents
treating
aggregation diseases
Prior art date
Application number
BR112021024151A
Other languages
English (en)
Portuguese (pt)
Inventor
Clarke Peterman Marshall
Santosh Sinha
Govinda Prasad Sridhar
Original Assignee
Plex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plex Pharmaceuticals Inc filed Critical Plex Pharmaceuticals Inc
Publication of BR112021024151A2 publication Critical patent/BR112021024151A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021024151A 2019-05-31 2020-06-01 Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho BR112021024151A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855560P 2019-05-31 2019-05-31
PCT/US2020/035592 WO2020243720A1 (en) 2019-05-31 2020-06-01 Pharmacological agents for treating protein aggregation diseases of the eye

Publications (1)

Publication Number Publication Date
BR112021024151A2 true BR112021024151A2 (pt) 2022-02-08

Family

ID=73553335

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024151A BR112021024151A2 (pt) 2019-05-31 2020-06-01 Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho

Country Status (8)

Country Link
US (1) US20220241247A1 (https=)
EP (1) EP3976017A4 (https=)
JP (1) JP2022534420A (https=)
CN (1) CN114173771A (https=)
BR (1) BR112021024151A2 (https=)
CA (1) CA3141998A1 (https=)
MX (1) MX2021014682A (https=)
WO (1) WO2020243720A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4097092A1 (en) * 2020-01-28 2022-12-07 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US20250019352A1 (en) * 2021-06-29 2025-01-16 Plex Pharmaceuticals, Inc. Pharmacological agents for treating ophthalmic diseases
WO2023009585A2 (en) * 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113523A1 (en) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
RU2586330C2 (ru) * 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
RU2747536C2 (ru) * 2011-10-24 2021-05-06 Сом Инновэйшн Биотек, С.Л. Новая терапия транстиретин-ассоциированного амилоидоза
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
RU2015138891A (ru) * 2013-03-08 2017-04-11 Аллерган, Инк. Конъюгаты антибиотиков, напрямую связанные со стероидными препаратами
PE20151747A1 (es) * 2013-03-14 2015-12-18 Univ Massachusetts Metodo para inhibir cataratas y presbicia
US11872236B2 (en) * 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Also Published As

Publication number Publication date
JP2022534420A (ja) 2022-07-29
CN114173771A (zh) 2022-03-11
US20220241247A1 (en) 2022-08-04
CA3141998A1 (en) 2020-12-03
MX2021014682A (es) 2022-04-06
WO2020243720A9 (en) 2021-02-04
WO2020243720A1 (en) 2020-12-03
EP3976017A4 (en) 2023-06-14
EP3976017A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
BR112021024151A2 (pt) Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BR112023002553A2 (pt) Composto, composição, uso do composto e uso da composição
BR112018075734A2 (pt) composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
JP2014525465A5 (https=)
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112022002630A2 (pt) Composição farmacêutica em pó seco adequada para administração por inalação, inalador de pó seco e método de tratamento ou prevenção de doenças ou condições
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022025946A2 (pt) Composto, composição farmacêutica e método de tratamento de uma doença
BR112021015744A2 (pt) Combinações de compostos de beta-lactama e probenecida e seu uso
BR112022001395A2 (pt) Métodos para administrar anticorpos anti-siglec-8 e corticosteroides
Schiappapietra et al. Glucocorticoids in juvenile idiopathic arthritis
BR112021024109A2 (pt) Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
BR112022026999A2 (pt) Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
BR112022006394A2 (pt) Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
BR112021022752A2 (pt) Composições e métodos para potencializar o efeito músculo-esquelético de um ou mais aminoácidos anabólicos
Schell et al. Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy
BR112012022052A2 (pt) método para o tratamento ou prevenção de sintomas da variação hormonal, composição farmacêutica para o tratamento ou prevenção de sintomas da variação hormonal e kit para o tratamento ou prevenção de sintomas da variação hormonal
BR112023025221A2 (pt) Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos
Zhou et al. Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice
Ganekal et al. Effect of topical calcium channel blockers on intraocular pressure in steroid-induced glaucoma

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements